Advanced Filters
noise

Esophageal Disorders Clinical Trials

A listing of Esophageal Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 717 clinical trials
P Pim Stougie

A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study

The investigators aim to study the rate of developing a biopsy-based diagnosis of high-grade dysplasia (HGD) and EAC in BE patients in a prospective cohort of 208 BE patients at high risk of progression (i.e. after endoscopic removal of visible lesions containing HGD/EAC and/or a diagnosis of low-grade dysplasia (LGD)) …

18 years of age All Phase N/A
Y Ying Nan Tsai, M.D

The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE

Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal …

20 years of age All Phase N/A

Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.

18 - 75 years of age All Phase 2
H H. WM van Laarhoven, M.D., PhD

TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

Despite treatment according to the CROSS-regimen, median overall survival is less than four years (2.3 QALYs). The burden of disease is within the highest category (0.71 to 1.0). Also, no targeted treatment options are currently available, hampering personalized treatment for this patient population. TRAP-2 aims to address these needs by …

18 years of age All Phase 3
P Pierre Cattan, MD PhD

Prospective Evaluation of the Results of Multidisciplinary Follow-up After a Transitional Consultation for Esophageal Atresia

A transition consultation for adult patients with esophageal atresia, involving medical and paramedical stakeholders, was set up at Hôpital Saint-Louis in 2020. The aim of this initiative is to: 1. initiate adult medical, psychological and social follow-up; 2. empower these adults in their future care; 3. establish a personalized follow-up …

18 - 30 years of age All Phase N/A
R Raphaelle MAUDINAS, MD

Long Term Outcome of Easophageal Atresia : Transmics Profiles in Adolescence

Oesophageal atresia (OAEA), a malformation of the oesophagus present from birth, is characterized by the interruption of the continuity of the oesophagus, which then ends in a cul-de-sac. (Source: Fimatho) An operation is then required to restore continuity to the esophagus. Although this operation enables the vast majority of children …

13 - 14 years of age All Phase N/A
R Raoul Furlano, PD MD

An Innovative Endoscopic Cap for Dilating Benign Esophageal Strictures in Children

The goal of this study is to find out if using the BougieCap device is a safe and effective way to stretch narrow areas in the esophagus (food pipe) in children. The main questions this study wants to answer are: Does the BougieCap work well to treat narrow areas in …

- 18 years of age All Phase N/A
F Feng Wang, phD

Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer

The Phase Ib stage of this study primarily aims to evaluate the tolerance and safety of TQB6411 Injection in subjects with recurrent or metastatic Esophageal cancer who have previously failed treatment with PD-1/PD-L1 monoclonal antibodies combined with platinum-based chemotherapy. The Phase II stage primarily aims to evaluate the efficacy of …

18 - 75 years of age All Phase 1/2

Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

This study is a prospective, single-arm, multicenter study. The patients were given chemotherapy with nimotuzumab and sindilimab. To analyze the efficacy and safety of nimotuzumab combined with sindilizumab and chemotherapy in first-line treatment of advanced or recurrent or metastatic esophageal cancer.

18 - 75 years of age All Phase 2
W Wen Cheng, M.D.

Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC

This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma. Aim to find the difference in efficacy and safety between tirilizumab combined with concurrent chemoradiation and standard concurrent chemoradiation. Concurrent chemoradiation is the standard treatment for elderly esophageal cancer. Tirelizumab is the first-line …

70 - 90 years of age All Phase 2

Simplify language using AI